<DOC>
	<DOCNO>NCT00242710</DOCNO>
	<brief_summary>The purpose study determine whether bazedoxifene/conjugated estrogen combination effective prevention endometrial hyperplasia prevention osteoporosis postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy , postmenopausal woman , age 40 less 65 year Intact uterus At least 12 month spontaneous amenorrhea , OR 6 month spontaneous amenorrhea folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL . Use oral estrogen , progestin , androgen , SERMcontaining drug product within 8 week screen ( 12 week osteoporosis substudy ) A history active presence clinically important medical disease Malabsorption disorder</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Endometrium</keyword>
	<keyword>Uterus</keyword>
	<keyword>Menopause</keyword>
</DOC>